Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today ...
The US multi-center Phase 1/2 clinical trial of spevatamig (NCT05482893) is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig in patients with advanced ...
The therapeutic landscape for lymphoma is undergoing a transformative shift, moving away from traditional cytotoxic intensification toward more targeted, mechanism-driven strategi ...
ABL Bio touts bispecific ADC gains, sets US trials for 206 and 209 Neoc Bio wins FDA clearance to begin phase 1 studies of ...
Earlier-line bispecific therapy leverages lower disease refractoriness to drive deeper, more durable responses than typically ...
A growing portfolio of in vivo-ready bispecific antibodies provides immediate access to anti-mouse and anti-human dual-target formats. Custom production options allow researchers to tailor constructs ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL ...
Bispecific antibodies (bispecifics) can simultaneously target two distinct antigens or epitopes, offering novel therapeutic strategies such as enhancing immune cell targeting of cancer cells or ...
Delhi, April 04, 2025 (GLOBE NEWSWIRE) -- Over the last two decades, immunotherapy has transformed treatment strategies across various medical fields. The effectiveness of monoclonal antibodies in ...
In this case, one arm of the antibody binds to an infected cell carrying cytomegalovirus proteins. The other arm attaches directly to a T cell. The antibody acts as a physical bridge, pulling the T ...
While 2025 has not been a banner year for biopharma dealmaking, antibodies that bind two or more molecular targets—so-called multispecifics—have taken center stage. The top three licensing deals and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results